Dartmouth-Hitchcock Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dartmouth-Hitchcock Medical Center sits in the top decile of US sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count).
Dartmouth-Hitchcock Medical Center: 427 sponsored US clinical trials, 52 recruiting.
Dartmouth-Hitchcock Medical Center sponsors 427 registered US clinical trials on ClinicalTrials.gov, 52 of them currently recruiting, and 300 completed. 25 of these trials are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.
Top-decile sponsor footprint
Dartmouth-Hitchcock Medical Center ranks in the top decile of sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
300 of 352 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
427 total, page 5 of 9
A Microdose Evaluation Study of ABY-029 in Primary Sarcoma
NCT03154411
CAREgiver Study for Patients Undergoing HSCT
NCT03210727
Community-Led Action Research in Oncology: Improving Symptom Management
NCT03208816
Ultrasound Guided Diagnostic Lumbar Puncture in Neurology
NCT03815045
Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion
NCT05270083
Lifestyle Intervention for Young Adults With Serious Mental Illness
NCT02815813
The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative
NCT03480854
Tele-BA for Home-Delivered Meals Clients
NCT04131790
Computer-based Prescription Opioid Abuse Prevention for Adolescents
NCT02737696
Low Frequency TMS for Depression in Epilepsy
NCT03105700
MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence
NCT02778282
Screen to Save: A Colorectal Cancer Educational Intervention
NCT03907579
The Appeal and Impact of E-cigarettes in Smokers With SMI
NCT03050853
A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
NCT02901925
Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts
NCT02752893
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02810704
Validation of Appropriateness Criteria for the Surgical Treatment of Lumbar Degenerative Spondylolisthesis
NCT02966639
Environmental Exposure and Neurological Diseases Questionnaire
NCT02916966
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
NCT02916979
MOWI Amulet Mobile Health Technology Validation
NCT03085589
MOWI Qualitative Assessment
NCT03041831
The Impact of Three Distinct Exercise Types on Fatigue, Anxiety, and Depression in Parkinson's Disease
NCT02885285
Right For Me: Birth Control Decisions Made Easier
NCT02759939
Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers
NCT02648178
Towards Detecting Cocaine Use Using Smartwatches in the NIDA Clinical Trials Network
NCT02915341
Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression
NCT03360942
ER Reactivation Therapy for Breast Cancer
NCT02188745
Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents
NCT02673541
Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study
NCT02575898
Preoperative Immersive Patient Quality Experience
NCT02619708
Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort
NCT02641171
Development of a Mobile System for Self-management of Schizophrenia (SOS)
NCT01969500
Treatment Decisions for Multi-vessel CAD
NCT02611050
Using Telehealth to Improve Psychiatric Symptom Management
NCT02710344
Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women
NCT02501239
A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers
NCT02550210
Phase I Study of the Combination of MLN9708 and Fulvestrant
NCT02384746
Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness
NCT02421965
Utilization of iMRI for Transsphenoidal Resection of Pituitary Macroadenomas
NCT02396810
Vacuum Assisted Closure for Cesarean Section
NCT02390401
Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance
NCT02405000
Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
NCT02409732
A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia
NCT01952041
Skin Care Behaviors Among Melanoma Survivors and Their Families
NCT02457065
Meditative Movement for COPD Symptoms in Non-Smoking Flight Attendants
NCT02612389
HOBSCOTCH Phase II
NCT02394509
Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer
NCT02306135
Prism Adaptation Treatment of Parkinson's Disease
NCT02380859
Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes
NCT02188732
Clinical Trial Tobacco Marijuana
NCT02277665
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 44 |
| Phase 2 | 40 |
| Phase 3 | 6 |
| Phase 4 | 19 |
Therapeutic Areas
What is open in the Dartmouth-Hitchcock Medical Center pipeline
52 recruiting of 427 indexed (12% open); 300 completed (70%).
Phase mix: 25 late (III/IV) vs 84 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dartmouth-Hitchcock Medical Center: open-pipeline peers nationwide
Peers matched on 427 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 427 trials (± recruiting share)
- University of Illinois at Chicago · 430 trials · 27% recruiting
- Vanderbilt University · 430 trials · 3% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- Novo Nordisk A/S · 431 trials · 8% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Friends Research Institute · 12% recruiting · 41 trials
- Antonios Likourezos · 12% recruiting · 33 trials
- Oregon State University · 12% recruiting · 33 trials
- University of Massachusetts, Amherst · 12% recruiting · 33 trials
Related
What to do with this Dartmouth-Hitchcock Medical Center page
427 registered trials is a research-attention snapshot, not an endorsement of Dartmouth-Hitchcock Medical Center or any single study.
- 52 of Dartmouth-Hitchcock Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dartmouth-Hitchcock Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Dartmouth-Hitchcock Medical Center pipeline card: 427 registered trials from official public datasets.Report a data error.